Evidence map›Paper›PMID 32953611›Full record

ArticleGland surgery2020

Standard-dose epirubicin increases the pathological complete response rate in neoadjuvant chemotherapy for breast cancer: a multicenter retrospective study.

Ben-Jie Shan, Xia-Bo Shen, Wei Jin, Meng-Hao Dong, Xing-Hua Han, Lin Lin, Jian Chen, Da-Bing Huang, Jun Qian, Jing-Jie Zhang and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gland surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
0.1field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Ben-Jie ShanDepartment of Medical Oncology, Anhui Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Xia-Bo ShenDepartment of Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Wei JinThe Fifth Ward of the Department of Tumor Chemotherapy, The First Affiliated Hospital of USTC & Anhui Provincial Cancer Hospital, Hefei, China.
Meng-Hao DongAnhui Provincial Hospital, Wannan Medical College, Wuhu, China.
Xing-Hua HanDepartment of Medical Oncology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Lin LinDepartment of Medical Oncology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Jian ChenDepartment of Medical Oncology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Da-Bing HuangDepartment of Medical Oncology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Jun QianDepartment of Tumor Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Jing-Jie ZhangDepartment of Breast Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yue-Yin PanDepartment of Medical Oncology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
University of Science and Technology of China · CNAnhui Provincial Hospital · CNFirst Affiliated Hospital of Anhui Medical University · CNFirst Affiliated Hospital of Bengbu Medical College · CNWannan Medical College · CNZhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoadjuvant chemotherapy (NAC) has become the best comprehensive treatment choice for breast cancer. Epirubicin is a crucial drug widely used in breast cancer chemotherapy, but it is often used with a reduced dosage in NAC for Chinese patients for its notable cardiotoxicity and frequent adverse events. This study aimed to investigate the efficacy and safety of standard-dose epirubicin in NAC for Chinese breast cancer patients retrospectively.

methodsWe retrospectively collected clinicopathological parameters of breast cancer patients who underwent epirubicin-based NAC and a later surgery from three separate medical centers. Patients were divided into standard-dose and low-dose groups according to the epirubicin dose. The pathological complete response (pCR) rate, as the main therapeutic outcomes, and the incidence of adverse events were recorded and compared.

resultsThe pCR rate of the standard-dose group was 41.2%, while the low-dose group was 10.1% (P<0.001). The univariate analysis showed that ER status (HR, 2.519; 95% CI, 1.057-5.988, P=0.037) and epirubicin dose (HR, 6.200; 95% CI, 2.374-16.193, P<0.001) were associated with pCR rates. The multivariate analysis showed that patients receiving standard-dose epirubicin chemotherapy (HR, 6.925; 95% CI, 2.537-18.902, P<0.001) showed more possibility to achieve pCR after NAC. There was no significant difference in the incidence rates of grade III/IV adverse events between these two different dose groups.

conclusionsStandard-dose epirubicin increases the pCR rate in breast cancer patients treated with NAC, and no other toxicity is noted.

Indexed as

breast cancerneoadjuvant chemotherapy (NAC)pathological complete response (pCR)Standard-dose epirubicin

Identifiers

PMID32953611
PMCPMC7475373
OpenAlexW3074506153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.